Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice

Microbiology and Immunology

Volumn 43, Issue 3, 1999, Pages 307-310

  Hwang, Eung Soo ^a   Kwon, Kyung Bae ^a   Park, Jae Won ^a   Kim, Dae Joong ^a   Park, Chung Gyu ^a   Cha, Chang Yong ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

DNA vaccine; Glycoprotein B; Human cytomegalovirus; Neutralizing antibody

Indexed keywords

DNA VACCINE; GLYCOPROTEIN; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CYTOMEGALOVIRUS; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PLACENTAL TRANSFER; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PURIFICATION; VIRUS IMMUNITY; VIRUS INFECTION;

ANIMALIA; CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 5;

EID: 0032999861     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.1999.tb02409.x     Document Type: Article

References (31)

1. Acsadi, G., Jiao, S.S., Jani, A., Duke, D., Williams, P., Chong, W., and Wolff, J.A. 1991. Direct gene transfer and expression into rat heart in vivo. New Biol. 3: 71-81.
2. Britt, W.J., Vugler, L., Butfiloski, E.J., and Stephens, E.B. 1990. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64: 1079-1085.
3. Britt, W.J., Vugler, L., and Stephens, E.B. 1988. Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J. Virol. 62: 3309-3318.
4. Davis, H.L., Demeneix, B.A., Quantin, B., Coulombe, J., and Whalen, R.G. 1993. Plasmid DNA is superior to viral vectors for direct gene transfer in adult mouse skeletal muscle. Hum. Gene Ther. 4: 733-740.
5. Davis, H.L., Michel, M.L., Mancini, M., Schleef, M., and Whalen, R.G. 1994. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine 12: 1503-1509.
6. Fiala, M., Payne, J.E., Berne, T.V., Moore, T.C., Henle, W., Montgomerie, J.Z., and Chatterjee, S.N. 1975. Epidemiology of cytomegalovirus infection after transplantation and immunosuppression. J. Infect. Dis. 132: 421-433.
7. Fowler, K.B., Stagno, S., Pass, R.F., Britt, W.J., Boll, T.J., and Alford, C.A. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326: 663-667.
8. Fynan, E.F., Webster, R.G., Fuller, D.H., Haynes, J.R., Santoro, J.C., and Robinson, H.L. 1995. DNA vaccines: a novel approach to immunization. Int. J. Immunopharmacol. 17: 79-83.
9. Gönczöl, E., Berencsi, K., Pincus, S., Endresz, V., Meric, C., Paoletti, E., and Plotkin, S.A. 1995. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13: 1080-1085.
10. Gönczöl, E., deTaisne, C., Hirka, G., Berencsi, K., Lin, W.C., Paoletti, E., and Plotkin, S. 1991. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 9: 631-637.
11. Gönczöl, E., Ianacone, J., Ho, W.Z., Star, S., Meignier, B., and Plotkin, S. 1990. Isolated gA/gB glycoprotein of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8: 130-136.
12. Hwang, E.S., Lim, D.G., Park, J.W., Park, C.G., Kook, Y.H., and Cha, C.Y. 1997. Eukaryotic expression of the major antigenic determinants evoking neutralizing antibodies in human cytomegalovirus (HCMV) isolated in Korea. J. Korean Soc. Microbiol. 32: 315-323.
13. Jacobson, M.A., and Mills, J. 1988. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 108: 585-594.
14. Justewicz, D.M., Morin, M.J., Robinson, H.L., and Webster, R.G. 1995. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J. Virol. 69: 7712-7717.
15. Kneiss, N., Mach, M., Fay, J., and Britt, W.J. 1991. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J. Virol. 65: 138-146.
16. Light, J.A., and Burke, D.S. 1979. Association of cytomegalovirus (CMV) infections with increased recipients mortality following transplantation. Transplant. Proc. 11: 79-82.
17. Lim, D.G., Park, C.G., Hwang, E.S., Chung, H.S., Park, J. W., and Cha, C.Y. 1995. Genomic sequence variation of the major antigenic determinants evoking neutralizing antibodies in HCMV isolated in Korea. J. Korean Soc. Microbiol. 30: 683-693.
18. Major, M.E., Vitvitski, L., Mink, M.A., Schleef, M., Whalen, R.G., Trepo, C., and Inchauspe, G. 1995. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol. 69: 5798-5805.
19. Marshall, G.S., Ricciardi, R.P., Rando, R.F., Puck, J., Ge, R., Plotkin, S.A., and Gönczöl, E. 1990. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J. Infect. Dis. 162: 1177-1181.
20. McDonnell, W.M., and Askari, F.K. 1996. DNA vaccines. N. Engl. J. Med. 334: 42-45.
21. Meyers, J.D., Spencer, H.C., Watts, J.C., Gregg, M.B., Stewart, J.A., Troupin, R.H., and Thomas, E.D. 1975. Cytomegalovirus pneumonia after human marrow transplantation. Ann. Intern. Med. 82: 181-188.
22. Navarro, D., Paz, P., Tugizov, S., Topp, K., La Vail, J., and Pereira, L. 1993. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 197: 143-158.
23. O'Reilly, R., Reich, L., Gold, J., Kirkpatrick, D., Dinsmore, R., Kapoor, N., and Condie, R. 1983. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: preliminary results. Transplant. Proc. 15: 1405-1411.
24. Park, C.G., Kwon, K.B., Park, J.W., Lim, D.G., Hwang, E.S., Kook, Y.H., Choi, S.B., and Cha, C.Y. 1997. Improved method for detecting neutralizing antibody against human cytomegalovirus by using specific monoclonal antibodies. J. Korean Soc. Microbiol. 31: 685-691.
25. Plotkin, S.A., Starr, S.E., Friedman, H.M., Brayman, K., Harris, S., Jackson, S., Tustin, N.B., Grossman, R., Dafoe, D., and Barker, C. 1991. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med. 114: 525-531.
26. Rasmussen, L. 1990. Immune response to human cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 154: 221-254.
27. Rasmussen, L., Matkin, C., Spaete, R., Pachl, C., and Merigan, T.C. 1991. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J. Infect. Dis. 164: 835-842.
28. Starr, S.E., Friedman, H.M., and Plotkin, S.A. 1991. The status of cytomegalovirus vaccine. Rev. Infect. Dis. 13 (Suppl. 11): S964-S965.
29. Winston, D.J., Ho, W.G., Lin, C.H., Bartoni, K., Budinger, M.D., Gale, R.P., and Chamlin, R.E. 1987. Intravenous immune globulin for prevention of cytomegalovirus infections and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 106: 12-18.
30. Wolff, J.A., Ludtke, J.J., Acsadi, G., Williams, P., and Jani, A. 1992. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1: 363-369.
31. Yeager, A.S., Grumet, F.C., Hafleigh, E.B., Arvin, A.M., Bradley, J.S., and Prober, C.G. 1981. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr. 98:281-287.